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Rosuvastatin Increases Extracellular Adenosine Formation
in Humans In Vivo
A New Perspective on Cardiovascular Protection
Patrick Meijer, Wim J.G. Oyen, Douwe Dekker, Petra H.H. van den Broek, Constatijn W. Wouters,
Otto C. Boerman, Gert Jan Scheffer, Paul Smits, Gerard A. Rongen
Objective—Statins may increase extracellular adenosine formation from adenosine monophosphate by enhancing
ecto-5-nucleotidase activity. This theory was tested in humans using dipyridamole-induced vasodilation as a read-out
for local adenosine formation. Dipyridamole inhibits the transport of extracellular adenosine into the cytosol resulting
in increased extracellular adenosine and subsequent vasodilation. In addition, we studied the effect of statin therapy in
a forearm model of ischemia-reperfusion injury.
Methods and Results—Volunteers randomly received rosuvastatin or placebo in a double-blind parallel design (n21).
The forearm vasodilator response to intraarterial dipyridamole was determined in the absence and presence of the
adenosine antagonist caffeine. During a separate visit the vasodilator response to nitroprusside and adenosine was
established. In addition, healthy men were randomly divided in 3 groups to receive either placebo (n10),
rosuvastatin (n22), or rosuvastatin combined with intravenous caffeine (n12). Subsequently, volunteers
performed forearm ischemic exercise. At reperfusion, Tc-99m–labeled annexin A5 was infused intravenously and
scintigraphic images were acquired, providing an early marker of cell injury. Rosuvastatin treatment significantly
increased the vasodilator response to dipyridamole, which was prevented by caffeine. Rosuvastatin did not
influence the response to either sodium nitroprusside or adenosine indicating a specific interaction between
rosuvastatin and dipyridamole, which does not result from an effect of rosuvastatin on adenosine clearance nor
adenosine-receptor affinity or efficacy. Rosuvastatin increased tolerance to ischemia-reperfusion injury, which was
attenuated by caffeine.
Conclusions—Rosuvastatin increases extracellular adenosine formation, which provides protection against ischemia-
reperfusion injury in humans in vivo. Therefore, statins and dipyridamole may interact synergistically. (Arterioscler
Thromb Vasc Biol. 2009;29:963-968.)
Key Words: adenosine  human  ischemia  rosuvastatin  annexin A5
Numerous clinical trials have documented protection by3-hydroxy-3-methylglutaryl coenzyme A reductase
(HMG-CoA reductase) inhibitors (statins) against cardiovas-
cular events.1–3 This benefit of statins has been attributed to
the lowering of plasma cholesterol. However, preclinical
research indicates that HMG-CoA reductase inhibition has
additional effects, including the activation of ecto-5-
nucleotidase which converses extracellular adenosine mono-
phosphate into adenosine.4–6 Increased adenosine formation
favorably influences cardiovascular disease by reducing
platelet aggregation,7 atherosclerosis formation,8 and ische-
mia-reperfusion injury.9 As statins possess similar properties,
adenosine is a possible candidate to mediate these ef-
fects.3,10–12 To our knowledge, the role of extracellular
adenosine formation in the benefit of statins has not been
explored in humans.
Here, we report on the results of 3 studies which addressed
the effect of rosuvastatin on adenosine formation and its
potential relevance in humans in vivo. For this purpose, we
used the adenosine receptor antagonist caffeine and the
nucleoside transport inhibitor dipyridamole, as pharmacolog-
ical tools to assess the involvement of endogenous adenosine
in statin-induced effects. Dipyridamole reduces clearance of
extracellular adenosine and therefore increases extracellular
adenosine concentration at sites of adenosine formation. The
subsequent increase in adenosine receptor stimulation is
responsible for dipyridamole-induced forearm vasodilation as
demonstrated previously.13 We reasoned that an increase in
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extracellular adenosine should result in an increased vasodi-
lator response to dipyridamole.
Forearm vascular tone and forearm injury in response to
ischemic exercise were used as end points. The following
hypotheses were tested:
1. A 1-week treatment with rosuvastatin augments the
forearm vasodilator response to dipyridamole without
affecting adenosine- or nitroprusside-induced vasodila-
tion. This potentiation is abolished by caffeine (study 1,
NCT00554138).
2. A 1-week treatment with rosuvastatin reduces injury
after forearm ischemic exercise as assessed with an-
nexin A5 scintigraphy (study 2, NCT00315510).
3. Caffeine inhibits the protective action of rosuvastatin




After the study protocols were approved by the Institutional Review
Board of the Radboud University Nijmegen Medical Centre, a total
of 60 healthy volunteers with a normal medical history, physical
examination, blood pressure, body mass index, fasting plasma lipid
profile, and glucose concentration gave written informed consent
before entering the studies. Eight volunteers participated in 2
different studies. Participants of study 2 were not allowed to
participate in study 3. Only male volunteers were allowed in the
studies with radiolabeled tracer. All studies were performed accord-
ing to institutional and Good Clinical Practice guidelines.
Study Design
Study 1: Rosuvastatin and Vasodilator Response
to Dipyridamole
Twenty-four volunteers were randomly allocated to receive either an
8-day treatment with rosuvastatin (Astra Zeneca SA, Destelbergen,
Belgium; 20 mg per day) or fully mimicking placebo (Pharmacy
Department HAGA hospital, The Hague, The Netherlands) in a
double blind design. Before (day 1) and during (day 7) treatment, the
vasodilator response to 4 increasing concentrations of intraarterial
dipyridamole was evaluated as previously described13 in the absence
and presence of an intraarterial infusion of caffeine (90 g/min/dL).
During a separate visit (day 8) vasodilator responses to intraarterially
infused sodium nitroprusside (SNP; Department of Clinical Phar-
macy, Radboud University Nijmegen Medical Centre), adenosine
(Sanofi Aventis), and 3 increasing periods of arterial occlusion were
determined as described previously.14
All experiments were performed after at least 24 hours of caffeine
abstinence, in the morning after an overnight fast, with exception of
the last experiment (day 8) which was performed in the afternoon
after a minimum fasting period of 6 hours. Volunteers were studied
in supine position in a temperature-controlled room (241°C). At
the start of each experiment a 27-gauge arterial needle (kindly
supplied by B. Braun Medical BV, Oss, The Netherlands) was
inserted into the brachial artery of the nondominant arm for intraar-
terial drug administration. In both arms forearm blood flow (FBF)
was measured simultaneously with venous occlusion plethysmogra-
phy using mercury-in-silastic-strain gauges and occluded hand cir-
culation as previously described.14 Total intraarterial infused volume
was kept at a constant rate of 150 L/min/dL forearm volume. Each
dose of vasodilator was infused into the brachial artery for 5 minutes.
Study 2: Rosuvastatin and Ischemia-Reperfusion Injury
Twenty volunteers randomly received either rosuvastatin (20 mg per
day for 7 days) or placebo (Pharmacy Department HAGA hospital,
The Hague, The Netherlands) in a double blind parallel design. One
hour after ingestion of the last trial medication, injury in response to
ischemic hand gripping was measured using previously described
experimental procedures.15 In brief, circulation to the nondominant
forearm was occluded for 10 minutes by inflating an upper arm cuff
to 200 mm Hg. From the start of occlusion, volunteers performed
rhythmic isometric hand contractions at 50% of their maximal
voluntary force for 5 seconds every 10-second period until exhaus-
tion. Immediately on reperfusion recombinant human annexin A5
labeled with Tc-99m (0.1 mg protein; 400 MBq) was administered
intravenously. Both hands were imaged at 1 and 4 hours of
reperfusion by using a gamma camera (Siemens Orbiter) connected
to a Hermes Gold image processing system (Nuclear Diagnostics).
Recombinant human annexin A5 was obtained from Theseus Imag-
ing Corporation and conjugated with HYNIC under GMP conditions
(Department of Clinical Pharmacy, Radboud University Nijmegen
Medical Centre). Labeling of this conjugated annexin with Tc-99m
was performed in the morning of administration (Department of
Nuclear Medicine, Radboud University Nijmegen Medical Centre)
as previously described.16
This forearm ischemia-reperfusion model detects the loss of
membrane asymmetry which results from phosphatidylserine (PS)
exposure on the outer membrane leaflet.15 Phosphatidylserine expo-
sition occurs shortly after an ischemic insult as an early, reversible,
sign of cell injury.17,18 Sustained exposition of phosphatidylserines is
involved in cell death.19,20 By labeling recombinant annexin A5 with
the -emitter Tc-99m, it is possible to visualize phosphatidylserine
exposure by gamma camera imaging. Annexin targeting after fore-
arm ischemia mimics infarct size in animals as it behaves similarly
in response to various interventions.15,16
Study 3: The Effect of Caffeine on Rosuvastatin-Induced
Forearm Protection Against Ischemia-Reperfusion Injury
Twenty-four volunteers received 20-mg rosuvastatin per day for 7
days and were randomly divided in 2 groups to receive either
intravenous normal saline or caffeine (4 mg/kg in ten minutes;
Genfarma) in a double-blind parallel design. Intravenous caffeine or
normal saline were administered 45 minutes before ischemic exer-
cise. One hour after the last intake of rosuvastatin, ischemic exercise
was performed and injury quantified as described for study 2.
Analytic Procedures
In all volunteers, blood was collected before and at the end of oral
treatment to determine fasting serum lipid profile (total-, HDL-, and
LDL-cholesterol and triglycerides), creatinine kinase (CK), and
alaninine amino transferase (ALAT) with a commercially available
kit (Aeroset, Abbott). Compliance to caffeine abstinence was mon-
itored by determination of plasma caffeine concentration before each
experiment. Plasma caffeine concentrations were determined by use
of reversed-phase HPLC with UV detection set at 273 nm according
to Schreiber-Deturmeny and Bruguerolle.21
Statistical Analysis
Study 1
Computer-assisted forearm blood flow analyses were performed
before unblinding. To correct for random changes in FBF unrelated
to the intervention the ratio of simultaneously measured FBF in
intervention and control arm was calculated (FBF-ratio). The FBF-
ratios of the last 4 minutes of reference measurements (during
intraarterial saline or saline plus caffeine as appropriate) and last 2
minutes of each dipyridamole, SNP, or adenosine dose-step were
averaged to 1 value. Peak FBF-ratio during postocclusive reperfu-
sion periods was used to determine the effect of rosuvastatin
treatment on postocclusive reactive hyperemia. Results are expressed
as percentage increase in FBF-ratio from reference measurements.
An ANOVA for repeated measures was used to determine treatment
related changes in the vasodilator response to dipyridamole with and
without caffeine (primary end point) and differences in the vasodi-
lator response to SNP, adenosine, and arterial occlusion (secondary
end points) between groups.
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Study 2 and 3
A predefined region of interest was identified for each hand
representing the thenar muscle. Within this region of interest
radioactivity was expressed as counts per pixel. Annexin A5 target-
ing after ischemic exercise was calculated as the percentage differ-
ence in radioactivity between the experimental and control hand. The
effect of rosuvastatin on annexin A5 targeting and the interaction
between rosuvastatin and caffeine was analyzed with an ANCOVA
for repeated measures with rosuvastatin and caffeine treatement as
between subject factors and workload as a covariate. Workload was
defined as the product of 50% of the maximal voluntary force and
duration of ischemic exercise. For this analysis, we combined both
studies by pooling 2 study arms (10 placebo, 22 rosuvastatin, and 12
rosuvastatin/caffeine treated individuals).
Paired Student t tests were used to detect treatment-related
changes in lipid profile within groups (secondary end point). All
results are expressed as meanSE, and a 2-sided probability value
0.05 was considered statistically significant.
Results
Study 1: Rosuvastatin and Vasodilator Response
to Dipyridamole
Before unblinding, 3 volunteers were excluded (2 in the
rosuvastatin group, 1 in the placebo group), leaving 11 and 10
evaluable subjects in the placebo and rosuvastatin-treated
arms, respectively. Reasons for exclusion were a defective
temperature control in the climate room (n1), development
of a common cold with a fever during the treatment period
(n1), and elevated plasma caffeine concentrations during all
visits (n1; 2.0 mg/L). In 1 volunteer, on treatment with
rosuvastatin, placement of the arterial needle failed on day 8.
Therefore, responses to intraarterial SNP and adenosine were
only available for 9 volunteers in the rosuvastatin-treated arm.
The baseline vasodilator response to dipyridamole did not
differ between the 2 treatment arms (Figure 1). Rosuvastatin
significantly reduced fasting plasma total- and LDL-choles-
terol (supplemental Table I, available online at http://atvb.
ahajournals.org). Rosuvastatin treatment did not influence
reference FBF-ratios nor the course of FBF in the control arm
between groups (data not shown). Rosuvastatin treatment
significantly increased the vasodilator response to dipyridam-
ole compared to placebo (Figure 1; P0.01). When analyzing
both groups separately, rosuvastatin augmented dipyridam-
ole-induced vasodilation as compared to baseline (P0.01),
whereas placebo treatment did not significantly alter this
response. In the presence of caffeine, the vasodilator response
to dipyridamole was significantly reduced and not signifi-
cantly influenced by treatment with rosuvastatin (Figure 1).
Treatment with rosuvastatin did not significantly affect the
vasodilator response to either SNP or adenosine. Rosuvastatin
significantly increased peak reactive hyperemia after 2, 5, and 13
minutes of arterial occlusion compared to placebo (Figure 2).
Study 2 and 3: The effect of Rosuvastatin and its
Interaction With Caffeine on Forearm
Ischemia-Reperfusion Injury
Treatment with rosuvastatin significantly reduced fasting
total cholesterol and LDL-cholesterol in both caffeine-treated
and -untreated study arms (supplemental Table I). Rosuvas-
tatin significantly reduced annexin A5 targeting: 213 and
253% in the placebo group versus 161 and 182% in the
rosuvastatin group. In rosuvastatin-treated volunteers who
received caffeine intravenously the reached plasma concen-
tration just before the ischemia-reperfusion protocol was
7.50.3 mg/L. In these volunteers annexin A5 targeting
tended to be higher as compared to rosuvastatin-treated
individuals who did not receive caffeine: 222 and 221%
(P0.07), thus reducing the effect of rosuvastatin (Figure 3).
Adverse Events
None of the volunteers reported side effects of treatment with
rosuvastatin or placebo. In 3 subjects (1 in study 2, 2 in study
Figure 1. Dipyridamole-induced forearm vasodila-
tion in the absence and presence of caffeine
before (baseline) and on treatment in placebo arm
(open squares) and rosuvastatin arm (closed
squares). Data are expressed as meanSE. Prob-
ability value indicates significant difference
between placebo and rosuvastatin arm. Caffeine
significantly reduced the vasodilator response to
dipyridamole in both treatment arms (P0.01). FBF
indicates forearm blood flow; FBF-ratio, FBF
experimental arm/FBF control arm.
Figure 2. The forearm vasodilator response after 8
days of treatment with either placebo (open
squares) or rosuvastatin (closed squares), to SNP
(sodium nitroprusside), adenosine, and arterial
occlusion. Data are expressed as meanSE. Prob-
ability value indicates significant difference
between placebo and rosuvastatin arm. FBF indi-
cates forearm blood flow; FBF-ratio, FBF experi-
mental arm/FBF control arm.
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3), all treated with rosuvastatin, a moderate (more than twice
the upper limit of normal) increase in CK was observed which
remained below 4000 U/L and returned to normal after the
study.
Discussion
This study indicates that rosuvastatin increases extracellular
adenosine formation and that this action may be involved in
the protection by rosuvastatin against ischemia-reperfusion
injury in humans in vivo. This conclusion is based on 2
key-findings: (1) rosuvastatin increases dipyridamole-
induced vasodilation without affecting adenosine-induced
vasodilation, and (2) rosuvastatin reduces targeting of an-




During normal physiological circumstances the transmem-
brane concentration gradient drives extracellular adenosine
into the cytosol.22,23 Dipyridamole inhibits this facilitated
diffusion in humans in vivo and thereby increases extracel-
lular adenosine concentration, which subsequently activates
adenosine receptors at sites of adenosine formation.13,14,24–26
These observations justify the use of dipyridamole-induced
vasodilation as a read-out of extracellular adenosine forma-
tion. Thus, if statins increase extracellular adenosine forma-
tion, this should result in a caffeine-sensitive augmentation of
dipyridamole-induced vasodilation. Our results proved this
hypothesis to be correct. Rosuvastatin did not significantly
affect the vasodilator response to adenosine in this group of
volunteers. This excludes an effect of rosuvastatin on aden-
osine clearance, adenosine receptors, or postreceptor signal-
ing as a potential explanation for our observations. Further-
more, the lack of effect of rosuvastatin on SNP-induced
vasodilation excludes nonspecific actions of rosuvastatin on
the vasodilator capacity of forearm vascular resistance ves-
sels. Therefore, the augmentation of dipyridamole-induced
vasodilation is explained by an increase in extracellular
formation of adenosine by rosuvastatin. Rosuvastatin en-
hanced postocclusive hyperemia, and this effect may be
implicated in statin-mediated protection against ischemia-
reperfusion injury. Further studies are needed to confirm the
involvement of adenosine receptors in this action of
rosuvastatin.
Rosuvastatin Reduces Targeting of Annexin A5
After Ischemic Exercise in the Absence but not in
the Presence of Caffeine
In this project, we used annexin A5 scintigraphy to investi-
gate the effect of rosuvastatin therapy on ischemia-
reperfusion injury. In addition, caffeine was used to reveal a
role of adenosine receptor stimulation in the observed benefit.
Like previously demonstrated in the heart,27 treatment with
a statin reduced ischemia-reperfusion injury in our forearm
model. In addition, our study reveals a potential role for
endogenous adenosine in this protective action of statins. We
have previously reported that caffeine does not affect annexin
A5 targeting after ischemic exercise in the absence of
rosuvastatin-pretreatment.16 Therefore, any effect of caffeine
on annexin targeting in the current study indicates a specific
interaction with rosuvastatin-pretreatment. Because plasma
lipids did not differ between the subjects treated with
rosuvastatincaffeine as compared with those treated with
rosuvastatin alone, the partial return of annexin targeting
after rosuvastatin treatment in response to caffeine sug-
gests that rosuvastatin-induced protection against ische-
mia-reperfusion injury is not explained by its effect on
plasma lipids alone. Because we powered our study pre-
suming caffeine to completely neutralize the effect of
rosuvastatin, the marginal probability value is probably
caused by an insufficient sample size.
Implications of Our Observations
Several trials have shown an additional benefit of aggressive
lipid lowering as a consequence of more effective inhibition
of HMG-CoA reductase, resulting in reduced progression or
even retardation of atherosclerosis.28 In contrast, the recently
published ENHANCE-trial failed to show such an effect on
IMT for the cholesterol absorption inhibitor on top of a statin,
despite additional reduction of LDL-C.29 This discrepancy
suggests that it may not be the additional reduction of LDL-C,
but other so called pleiotropic actions of statins that are
responsible for the observed incremental benefit of intensi-
fied statin treatment. Upregulation of ecto-5-nucleotidase
and subsequent increases in extracellular adenosine formation
may be one of these. Indeed, studies in ecto-5-nucleotidase-
deficient mice indicate an important role for this enzyme in
the prevention of vascular inflammation and subsequent
atherosclerosis formation in wild-type mice.8
Besides reducing atherosclerosis, statins also limit ische-
mia-reperfusion injury. The ARMYDA-ACS trial showed
that this effect occurs within 12 hours in patients undergoing
percutaneous coronary intervention,27 and further disproves
LDL-C as the sole target of statin therapy. Blockade of
mevalonate formation, the principle action of HMG-CoA
reductase inhibitors, not only reduces cholesterol synthesis in
the liver but also reduces levels of isoprenoid derivatives
which play an important role in isoprenylation of small
GTPases of the Rho/Rac/Cdc42 family such as RhoA. This
action of statins has recently been implicated in their protec-
tion against ischemia-reperfusion injury in kidney, heart, and
Figure 3. Annexin A5 targeting after ischemic exercise. Ischemic
exercise was performed after a 24-hour abstinence from caf-
feine containing beverages. Subjects had been randomly allo-
cated to a 1-week treatment with placebo (open squares), rosu-
vastatin (closed squares), or rosuvastatin in combination with a
caffeine infusion 45 minutes before the ischemic exercise
(closed triangles). Data are expressed as meanSE. Rosuvasta-
tin significantly reduced annexin targeting. This action was
inhibited by intravenous caffeine.
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brain,30–32 possibly by activating 5-ecto-nucleotidase.6 In
concurrence, animal experiments have shown an acute effect
of statins on ischemia-reperfusion injury by increased aden-
osine receptor stimulation.5 Increased availability of adeno-
sine enlarges the reflow area after an ischemic event, which
reduces the area with ongoing ischemia during reperfusion.
Moreover, release of adenosine and subsequent stimulation of
adenosine receptors are essential in mediating ischemic pre-
conditioning,16,33,34 which increases cellular resilience to
ischemia-reperfusion injury.35 In the present study, caffeine,
in a concentration reached after 2 to 3 cups of coffee,36,37
attenuated protection by rosuvastatin against sequelae of
ischemic exercise. This is in line with previous studies in the
rat and dog heart.5,38 Therefore, we claim that adenosine plays
a key role in statin-induced increased tolerance to ischemia-
reperfusion injury in humans in vivo.
The effect of statins on adenosine formation opens a new
window for optimizing their clinical effect. Indeed this has
been demonstrated in animals in which the combination of a
low dose of atorvastatin and dipyridamole reduced ischemia-
reperfusion injury where the individual agents did not.39
Although the influence of daily caffeine consumption on
statin induced protection has not been investigated in a
clinical setting, the combined use of caffeine and statins will
be regularly encountered. Despite lingering controversy about
the effect of coffee consumption on cardiovascular disease in
the general population, specific subgroups of patients may be
prone to the adverse effect of adenosine receptor blockade.40
In particular, our results predict that in cardiovascular patients
the short-term use of caffeine will reduce the therapeutic
action of statins.
In conclusion, rosuvastatin increases extracellular adeno-
sine formation. Increased adenosine formation as a result of
statin treatment likely contributes to its protection against
ischemia-reperfusion injury. Preclinical evidence from the
literature suggests that this action may also be involved in the
prevention of atherosclerosis by statins. Future studies will
have to focus on the optimal exploitation of this property of
statins in patient care. This may ultimately lead to improved
tailoring of drug therapy to patients at risk for cardiovascular
events in which the combination of rosuvastatin and dipyri-
damole may provide synergistic benefits.
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Table 1. Effect of treatment on lipid profile 
 Study 1  Study 2 and 3 









Rosuvastatin / caffeine 
(n=12) 
Day 1        
Fasting total cholesterol (mmol/L) 3·8  0·2 3·6  0·1  4·2  0·2 4·2  0·2 4·7  0·3 
Fasting LDL-cholesterol (mmol/L) 2·2  0·1 2·1  0·1  2·5  0·2 2·6  0·2 2·8  0·2 
Fasting triglycerides (mmol/L) 0·6  0·1 0·6  0·1  1·3  0·2 1·0  0·1 1·1  0·2 
Fasting HDL-cholesterol (mmol/L) 1·3  0·1 1·2  0·1  1·2  0·1 1·2  0·05 1·4  0·1 
       
Day 7       
Fasting total cholesterol (mmol/L) 3·9  0·2 2·6  0·2 *  4·2  0·2 3·3  0·2 * 3·3  0·2 * 
Fasting LDL-cholesterol (mmol/L) 2·2  0·2 1·2  0·1 *  2·5  0·2 1·7  0·2 * 1·6  0·2 * 
Fasting triglycerides (mmol/L) 0·7  0·1 0·5  0·1   1·4  0·2 0·7  0·1 *  0·9  0·2  
Fasting HDL-cholesterol (mmol/L) 1·3  0·1 1·2  0·1   1·2  0·1 1·3  0·1 1·3  0·1 
* P < 0·001 day 1 versus day 7, paired T-test. Study 1: Rosuvastatin and vasodilator response to dipyridamole; Study 2 and 3: Rosuvastatin and 
ischemia-reperfusion injury and its interaction with caffeine. Data are expressed as mean  SE. 
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